Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, Rondelli R, Masetti R, Putti MC, Fagioli F, Rizzari C, Pession A, Locatelli F, Basso G. Pigazzi M, et al. Among authors: rizzari c. Haematologica. 2015 Mar;100(3):e99-101. doi: 10.3324/haematol.2014.114579. Epub 2014 Dec 5. Haematologica. 2015. PMID: 25480496 Free PMC article. No abstract available.
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction.
Möricke A, Rizzari C, Alten J, Attarbaschi A, Beier R, Biondi A, Burkhardt B, Bodmer N, Boos J, Cario G, Conter V, Flotho C, Kulozik A, Lanvers-Kaminsky C, Mann G, Niggli F, Silvestri D, von Stackelberg A, Stanulla M, Valsecchi MG, Schrappe M, Zimmermann M. Möricke A, et al. Among authors: rizzari c. Hemasphere. 2023 Jun 1;7(6):e888. doi: 10.1097/HS9.0000000000000888. eCollection 2023 Jun. Hemasphere. 2023. PMID: 37275738 Free PMC article. No abstract available.
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G, et al. Conter V, et al. Among authors: rizzari c. J Clin Oncol. 1995 Oct;13(10):2497-502. doi: 10.1200/JCO.1995.13.10.2497. J Clin Oncol. 1995. PMID: 7595699 Clinical Trial.
Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
Aricò M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G. Aricò M, et al. Among authors: rizzari c. Cancer. 1995 Apr 1;75(7):1684-93. doi: 10.1002/1097-0142(19950401)75:7<1684::aid-cncr2820750720>3.0.co;2-2. Cancer. 1995. PMID: 8826928
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G. Conter V, et al. Among authors: rizzari c. Haematologica. 1998 Sep;83(9):791-9. Haematologica. 1998. PMID: 9825576 Clinical Trial.
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C, Valsecchi MG, Aricò M, Conter V, Testi A, Barisone E, Casale F, Lo Nigro L, Rondelli R, Basso G, Santoro N, Masera G; Associazione Italiano Ematologia Oncologia Pediatrica. Rizzari C, et al. J Clin Oncol. 2001 Mar 1;19(5):1297-303. doi: 10.1200/JCO.2001.19.5.1297. J Clin Oncol. 2001. PMID: 11230471 Clinical Trial.
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
Aricò M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, Barisone E, Poggi V, De Rossi G, Locatelli F, Micalizzi MC, Basso G, Masera G. Aricò M, et al. Among authors: rizzari c. Blood. 2002 Jul 15;100(2):420-6. doi: 10.1182/blood.v100.2.420. Blood. 2002. PMID: 12091331 Free article. Clinical Trial.
176 results